Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
Authors:
- Tamio TeramotoTTTamio Teramoto
- Masayoshi ShirakawaMSMasayoshi Shirakawa
- Masashi KikuchiMKMasashi Kikuchi
- Mariko NakagomiMNMariko Nakagomi
- Satoko TamuraSTSatoko Tamura
- Howard K. SurksHSHoward K. Surks
- Christine McCrary SiskCSChristine McCrary Sisk
- Hirotaka NumaguchiHNHirotaka Numaguchi
- 1 September 2013
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 230 (1) , 52-60
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibJournal of Lipid Research, 2013
- Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapibJournal of Lipid Research, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEuropean Heart Journal, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein BArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Summary estimates of cholesterol used to predict coronary heart disease.Circulation, 1983